A private business has helped supercharge a controversial federal drug program. Patients and insurers have been left with big bills.
Related Posts
Susan F. Wood, Who Resigned From the F.D.A. Over Plan B, Dies at 66
She left the agency because of its delay in approving the morning-after pill for over-the-counter use. Her resignation drew national…
First Sickle Cell Gene Therapy Patient, 12, Leaves Hospital
After 44 days, Kendric Cromer, 12, left the hospital. While his family feels fortunate that he was the first to…
Health Concerns Mount for Migrant Children at Outdoor Holding Sites
To Dr. Theresa Cheng, the scene was “apocalyptic.” She had come to Valley of the Moon, an open-air holding site…